Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries
© 2024 The Authors..
In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
The Lancet regional health. Europe - 38(2024) vom: 31. März, Seite 100838 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Jager, Vincent D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Europe |
|---|
| Anmerkungen: |
Date Revised 14.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.lanepe.2024.100838 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36966454X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36966454X | ||
| 003 | DE-627 | ||
| 005 | 20240315000000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lanepe.2024.100838 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM36966454X | ||
| 035 | |a (NLM)38476742 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Jager, Vincent D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness. Moreover, the availability of recently EMA-approved targeted therapies varies between European countries. Unfortunately, routine assessment of national/regional molecular testing rates is limited. As a result, it remains uncertain which proportion of patients with metastatic NSCLC in Europe receive adequate predictive biomarker testing. Lastly, Molecular Tumor Boards (MTBs) for discussion of molecular test results are widely implemented, but national guidelines for their composition and functioning are lacking. The establishment of MTB guidelines can provide a framework for interpreting rare or complex mutations, facilitating appropriate treatment decision-making, and ensuring quality control | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Europe | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a Predictive biomarker testing | |
| 650 | 4 | |a Targeted therapy | |
| 700 | 1 | |a Timens, Wim |e verfasserin |4 aut | |
| 700 | 1 | |a Bayle, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Botling, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Brcic, Luka |e verfasserin |4 aut | |
| 700 | 1 | |a Büttner, Reinhard |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandes, Maria Gabriela O |e verfasserin |4 aut | |
| 700 | 1 | |a Havel, Libor |e verfasserin |4 aut | |
| 700 | 1 | |a Hochmair, Maximilian J |e verfasserin |4 aut | |
| 700 | 1 | |a Hofman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Janssens, Annelies |e verfasserin |4 aut | |
| 700 | 1 | |a Johansson, Mikael |e verfasserin |4 aut | |
| 700 | 1 | |a van Kempen, Léon |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Izidor |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Rios, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Lüchtenborg, Margreet |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, José Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Mohorcic, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Paz-Ares, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Popat, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Ryška, Aleš |e verfasserin |4 aut | |
| 700 | 1 | |a Taniere, Phillipe |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Schuuring, Ed |e verfasserin |4 aut | |
| 700 | 1 | |a van der Wekken, Anthonie J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet regional health. Europe |d 2021 |g 38(2024) vom: 31. März, Seite 100838 |w (DE-627)NLM323979734 |x 2666-7762 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2024 |g day:31 |g month:03 |g pages:100838 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lanepe.2024.100838 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2024 |b 31 |c 03 |h 100838 | ||